Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Post-transplant cyclophosphamide based GVHD prophylaxis in HLA-matched related and unrelated donor hematopoietic cell transplantation in adults with hematologic malignancies undergoing myeloablative conditioning: A CIBMTR analysis of 8,272 participants

View Full Paper
Ask AI
Bookmark
Share

Authors

RNRajneesh NathPKPooja KhandelwalSSStephen Spellman

Discussion

Loading...

Member takes

Overview

Analysis finds improved GVHD-free survival in adults undergoing HCT with PTCy-based compared to CNI/MTX, highlighting treatment efficacy.

Key Points

  • To compare 2-year GVHD-free, relapse-free survival between PTCy-based and CNI/MTX-based GVHD prophylaxis in adults undergoing myeloablative HCT.
  • Assessment of outcomes from the CIBMTR database with 8272 participating adults
  • Comparison between PTCy-based and CNI/MTX-based prophylaxis
  • Multivariable regression analysis using Cox proportional hazards models.
  • At 2 years, GRFS was 41.2% in PTCy cohort vs 25.8% in CNI/MTX with ATG and 17.5% in CNI/MTX cohorts
  • PTCy was associated with significantly lower treatment-related mortality and lower aGVHD incidences
  • No difference in disease-free survival was noted between cohorts.

Cite This Study

Nath et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc9bhttps://doi.org/10.1182/blood-2025-931
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation2025
  2. 2Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry2025
  3. 3Safety and efficacy of post transplant cyclophosphamide vs tacrolimus plus methotrexate for gvhd prophylaxis in myelofibrosis2025
  4. 4Post-transplant cyclophosphamide-based graft-verses-host disease (GVHD) prophylaxis is associated with a low incidence of fibrotic chronic GVHD after allogeneic hematopoietic cell transplantation across diverse donor types2025
  5. 5Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study2025